159 related articles for article (PubMed ID: 23717047)
1. Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany.
Klussmann JP; Schädlich PK; Chen X; Rémy V
Clinicoecon Outcomes Res; 2013; 5():203-13. PubMed ID: 23717047
[TBL] [Abstract][Full Text] [Related]
2. Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany.
Heitland W; Schädlich PK; Chen X; Rémy V; Moro L
J Med Econ; 2013; 16(3):364-71. PubMed ID: 23253056
[TBL] [Abstract][Full Text] [Related]
3. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
4. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
5. Modeling the cost of influenza: the impact of missing costs of unreported complications and sick leave.
Xue Y; Kristiansen IS; de Blasio BF
BMC Public Health; 2010 Nov; 10():724. PubMed ID: 21106057
[TBL] [Abstract][Full Text] [Related]
6. Economic Burden of Cervical and Head and Neck Cancer in Taiwan from a Societal Perspective.
Wu YH; Lai CH; Chien L; Pan YC; Lin YJ; Feng C; Chang CJ
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36834412
[TBL] [Abstract][Full Text] [Related]
7. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
8. The burden of varicella in Germany. Potential risks and economic impact.
Banz K; Wagenpfeil S; Neiss A; Hammerschmidt T; Wutzler P
Eur J Health Econ; 2004 Feb; 5(1):46-53. PubMed ID: 15452764
[TBL] [Abstract][Full Text] [Related]
9. The economic burden of human papillomavirus infection-associated diseases in the Republic of Korea, 2002-2015.
Ki M; Choi HY; Han M; Oh JK
Vaccine; 2018 Jul; 36(31):4633-4640. PubMed ID: 29961603
[TBL] [Abstract][Full Text] [Related]
10. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts.
Jönsen A; Hjalte F; Willim M; Carlsson KS; Sjöwall C; Svenungsson E; Leonard D; Bengtsson C; Rantapää-Dahlqvist S; Pettersson S; Gunnarsson I; Zickert A; Gustafsson JT; Rönnblom L; Petersson IF; Bengtsson AA; Nived O
Semin Arthritis Rheum; 2016 Jun; 45(6):684-90. PubMed ID: 26743074
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and costs in 23-25-year-old women with human papillomavirus (HPV) associated anogenital diseases in Germany - a retrospective analysis of statutory health insurance claims data.
Reuschenbach M; Mihm S; Wölle R; Schneider KM; Jacob C; Greiner W; Hampl M; Goodman E
BMC Health Serv Res; 2022 Aug; 22(1):1002. PubMed ID: 35932066
[TBL] [Abstract][Full Text] [Related]
12. Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study.
Mennini FS; Fabiano G; Marcellusi A; Sciattella P; Saia M; Cocchio S; Baldo V
Clin Drug Investig; 2018 Feb; 38(2):173-180. PubMed ID: 29081028
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of HPV-related cancers in France.
Borget I; Abramowitz L; Mathevet P
Vaccine; 2011 Jul; 29(32):5245-9. PubMed ID: 21616117
[TBL] [Abstract][Full Text] [Related]
14. Economic burden of human papillomavirus-related diseases in Italy.
Baio G; Capone A; Marcellusi A; Mennini FS; Favato G
PLoS One; 2012; 7(11):e49699. PubMed ID: 23185412
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological and economic burden of potentially HPV-related cancers in France.
Abramowitz L; Lacau Saint Guily J; Moyal-Barracco M; Bergeron C; Borne H; Dahlab A; Bresse X; Uhart M; Cancalon C; Catella L; Bénard S
PLoS One; 2018; 13(9):e0202564. PubMed ID: 30235216
[TBL] [Abstract][Full Text] [Related]
16. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Economic Burden of Relapses in Neuromyelitis Optica Spectrum Disorder: A Real-World Analysis Using German Claims Data.
Knapp RK; Hardtstock F; Wilke T; Maywald U; Deiters B; Schneider S; Mouchet J
Neurol Ther; 2022 Mar; 11(1):247-263. PubMed ID: 34940956
[TBL] [Abstract][Full Text] [Related]
18. Assessing the burden of HPV-related head and neck cancers in mainland China: protocol of a nationwide, multisite, cross-sectional study.
Wang W; Song C; Su Z; Kothari S; Chen YT; Liu Y; Wu SY; Panchal R; Morais E; Zhang SK; Yin J; Qiao YL; Roberts C
BMJ Open; 2023 Nov; 13(11):e073277. PubMed ID: 37968007
[TBL] [Abstract][Full Text] [Related]
19. Economic burden of neural tube defects in Germany.
Bowles D; Wasiak R; Kissner M; van Nooten F; Engel S; Linder R; Verheyen F; Greiner W
Public Health; 2014 Mar; 128(3):274-81. PubMed ID: 24559770
[TBL] [Abstract][Full Text] [Related]
20. The societal cost of schizophrenia in Sweden.
Ekman M; Granstrom O; Omerov S; Jacob J; Landen M
J Ment Health Policy Econ; 2013 Mar; 16(1):13-25. PubMed ID: 23676412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
